1. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia
by Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, and Jennifer R. Brown
BloodAdv
Volume 3(7):
April 9, 2019
© 2019 by The American Society of Hematology

2. Benjamin L. Lampson et al. Blood Adv 2019;3:1167-1174
© 2019 by The American Society of Hematology

3. Trial profile. Trial profile.
Benjamin L. Lampson et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Best nodal response to treatment with idelalisib and ofatumumab in evaluable patients.
Best nodal response to treatment with idelalisib and ofatumumab in evaluable patients. Best nodal response for 24 patients evaluable for lymph node response (3 patients were not evaluable: 1 because of lack of baseline adenopathy and 2 because of short duration of treatment without follow-up scans before receiving the next line of therapy). Blue bars represent patients with TP53 aberrant disease. SPD, sum of the products of the perpendicular diameters of measured lymph nodes.
Benjamin L. Lampson et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

5. PFS and OS in all patients.
Benjamin L. Lampson et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

6. Correlation between duration of treatment and time to progression or death.
Correlation between duration of treatment and time to progression or death. Only data points from the 19 patients who had disease progression or death are included.
Benjamin L. Lampson et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology